SEC Form 4 · accession 0001144204-16-128963
INTERLEUKIN GENETICS INC · ILIU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Mark B Carbeau
Officer — CEO · Director
Period of report
Oct 20, 2016
Accepted (ET)
Oct 21, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001037649
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1,F3 | $0.1754 | Oct 20, 2016 | A | 5,000,000 | A | — | Oct 20, 2026 | Common Stock | 5,000,000 | 5,000,000 | D |
Explanation of responses
- F1The exercise price of the option is the closing price of the Issuer's common stock on the OTCQB on October 20, 2016, which was the grant date of the option.
- F2The option was granted pursuant to the terms of Mr. Carbeau's employment agreement, dated April 6, 2015, which provided that he would be entitled to such a grant following a Qualified Financing (as defined in the agreement) for Interleukin Genetics, Inc.
- F3The option vests as to 25% of the shares on October 20, 2017, and 1/36th of the shares on the first day of each month beginning on November 1, 2017.